ClinicalTrials.gg
CompletedNCT04840888Updated Dec 11, 2025Results posted

A Study of LY3484356 in Healthy Female Participants

A Phase 1 interventional study of LY3484356 and Omeprazole in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The main purpose of this study is to evaluate the amount of LY3484356 that is found in the blood stream and how long the body takes to get rid of it when given with and without food. Participants are healthy females of non-childbearing potential. The study will also evaluate the tolerability and safety of LY3484356 by collecting the information about any side effects that may occur. The participant's involvement with the study will last approximately 27 days, not including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical assessment
  • (BMI) within the range 18.0 to 35.0 kilograms per meter squared (kg/m²)
  • Female participants of non . This includes females who are not pregnant, non-lactating and either: Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or bilateral salpingectomy, bilateral tubal ligation, or bilateral tubal occlusion), or alternate medical cause/congenital anomaly (for example, Müllerian agenesis) or

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of cardiovascular (eg, symptomatic bradycardia with resting heart rate of \<60 beats per minute), respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
  • Show evidence of , evidence of and/or have evidence of (HIV) infection
  • Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing
  • Use or intend to use medications that inhibit or induce within 14 days prior to dosing until completion of the follow-up visit
  • Smoke more than 10 cigarettes or use the equivalent tobacco, smoking-cessation products, nicotine-containing products, or e cigarettes (nicotine and non nicotine) per day
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Cohort 1 Sequence 1: 400 mg LY3484356 Fasted/ 400 mg LY3484356 Fed

    Participants were randomized (1:1) to 1 of 2 treatment sequences; LY3484356 administered as single doses orally with (fed) or without food (fasted) as below: Period 1: Single dose of 400 mg LY3484356 in the fasted state. Period 2: Single dose of 400 mg LY3484356 in the fed state. There was a washout period of 4 days between doses of LY3484356

    Drug: LY3484356

  • Experimental
    Cohort 1 Sequence 2: 400 mg LY3484356 Fed/ 400 mg LY3484356 Fasted

    Participants were randomized (1:1) to 1 of 2 treatment sequences; LY3484356 administered as single doses orally with (fed) or without food (fasted) as below: Period 1: Single dose of 400 mg LY3484356 in the fed state. Period 2: Single dose of 400 mg LY3484356 in the fasted state. There was a washout period of 4 days between doses of LY3484356.

    Drug: LY3484356

  • Experimental
    Cohort 2: LY3484356 + Omeprazole

    Participants received single dose of LY3484356 and a single dose of omeprazole alone and in combination administered orally as below: Day 1: 400 mg LY3484356 alone Days 5 to 8: 40 mg omeprazole alone once daily Day 9: 400 mg LY3484356 + 40 mg omeprazole once There was a washout period of 8 days between doses of LY3484356.

    Drug: LY3484356 · Drug: Omeprazole

  • Experimental
    Cohort 3: LY3484356 + Itraconazole

    Participants received single dose of LY3484356 and a single dose of Itraconazole alone and in combination administered orally as below: Day 1: 200 mg LY3484356 alone Days 5 to 9: 200 mg itraconazole alone (twice on Day 5 \[dose separated by approximately 12 hours\], then once daily on Days 6 through 9) Day 10: 200 mg LY3484356 + 200 mg itraconazole once (coadministered with the morning dose) Days 11 to 16: 200 mg itraconazole alone once daily. There was a washout period of 9 days between doses of LY3484356.

    Drug: LY3484356 · Drug: Itraconazole

  • Experimental
    Cohort 4: LY3484356 + Carbamazepine

    Participants received single dose of LY3484356 and a single dose of carbamazepine alone and in combination administered orally as below: Day 1: 400 mg LY3484356 alone Days 6 to 8: 100 mg carbamazepine BID alone Days 9 to 11: 200 mg carbamazepine BID alone Days 12 to 17: 300 mg carbamazepine BID alone Day 18: 300 mg carbamazepine BID + 400 mg LY3484356 (coadministered with morning dose) Days 19 to 22: 300 mg carbamazepine BID alone Day 23: 300 mg carbamazepine alone (morning dose only). There was a washout period of 17 days between doses of LY3484356.

    Drug: LY3484356 · Drug: Carbamazepine

  • Experimental
    Cohort 5: Carbamazepine + Midazolam

    Participants received single dose of Carbamazepine and a single dose of midazolam alone and in combination administered orally as below: Day 1: 1.2 mg midazolam alone Days 2 to 4: 100 mg carbamazepine BID alone Days 5 to 7: 200 mg carbamazepine BID alone Days 8 to 10: 300 mg carbamazepine BID alone Day 11: 300 mg carbamazepine BID + 1.2 mg midazolam (coadministered with morning dose) Days 12 to 13: 300 mg carbamazepine BID alone Day 14: 300 mg carbamazepine BID + 1.2 mg midazolam (coadministered with morning dose).

    Drug: Carbamazepine · Drug: Midazolam

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356 (Cohort 1)

    PK: AUC\[0-∞\] of LY3484356

    Time frame: Period 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours (h) postdose; Period 2: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 and 96 h postdose

  2. PK: AUC[0-∞] of LY3484356 (Cohort 2)

    PK: AUC\[0-∞\] of LY3484356

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 9: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose

  3. PK: AUC[0-∞] of LY3484356 (Cohort 3)

    PK: AUC\[0-∞\] of LY3484356

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 10: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose

  4. PK: AUC[0-∞] of LY3484356 (Cohort 4)

    AUC\[0-∞\] of LY3484356

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 18: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose

  5. PK: Time of Maximum Observed Concentration (Tmax) of LY3484356 (Cohort 1)

    PK: Tmax of LY3484356

    Time frame: Period 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 h postdose; Period 2: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 and 96 h postdose

  6. PK: Tmax of LY3484356 (Cohort 2)

    PK: Tmax of LY3484356

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 9: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose

  7. PK: Tmax of LY3484356 (Cohort 3)

    PK: Tmax of LY3484356

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 10: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose

  8. PK: Tmax of LY3484356 (Cohort 4)

    Tmax of LY3484356

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 18: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose

  9. PK: Maximum Observed Concentration (Cmax) of LY3484356 (Cohort 1)

    Cmax of LY3484356

    Time frame: Period 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 h postdose; Period 2: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 and 96 h postdose

  10. PK: Cmax of LY3484356 (Cohort 2)

    Cmax of LY3484356

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 9: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose

  11. PK: Cmax of LY3484356 (Cohort 3)

    Cmax of LY3484356

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 10: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose

  12. PK: Cmax of LY3484356 (Cohort 4)

    Cmax of LY3484356

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 18: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose

07

Results

Posted Dec 11, 2025

Participant flow

Period 1
Participant flow — Period 1
MilestoneCohort 1 Sequence 1: 400 mg LY3484356 Fasted/ 400 mg LY3484356 FedCohort 1 Sequence 2: 400 mg LY3484356 Fed/ 400 mg LY3484356 FastedCohort 2: LY3484356 + OmeprazoleCohort 3: LY3484356 + ItraconazoleCohort 4: LY3484356 + CarbamazepineCohort 5: Carbamazepine + Midazolam
Started5310202915
Received at least one dose of study drug5310202915
Completed539191814
Not completed0011111
Withdrew: Withdrawal by subject000010
Withdrew: Adverse event0011101
Period 2
Participant flow — Period 2
MilestoneCohort 1 Sequence 1: 400 mg LY3484356 Fasted/ 400 mg LY3484356 FedCohort 1 Sequence 2: 400 mg LY3484356 Fed/ 400 mg LY3484356 FastedCohort 2: LY3484356 + OmeprazoleCohort 3: LY3484356 + ItraconazoleCohort 4: LY3484356 + CarbamazepineCohort 5: Carbamazepine + Midazolam
Started530000
Received at least one dose of study drug530000
Completed530000
Not completed000000

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356 (Cohort 1)

PK: AUC\[0-∞\] of LY3484356

Time frame:
Period 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours (h) postdose; Period 2: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 and 96 h postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356 (Cohort 1)
nanogram*hour per milliliter (ng*hr/mL)Cohort 1: 400 mg LY3484356 FastedCohort 1: 400 mg LY3484356 Fed
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356 (Cohort 1)1810 ± 594350 ± 39
PrimaryPK: AUC[0-∞] of LY3484356 (Cohort 2)

PK: AUC\[0-∞\] of LY3484356

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 9: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC[0-∞] of LY3484356 (Cohort 2)
ng*hr/mLCohort 2: LY3484356 + Omeprazole
Day 12270 ± 93
Day 91960 ± 46
PrimaryPK: AUC[0-∞] of LY3484356 (Cohort 3)

PK: AUC\[0-∞\] of LY3484356

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 10: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC[0-∞] of LY3484356 (Cohort 3)
ng*hr/mLCohort 3: LY3484356 + Itraconazole
Day 11430 ± 58
Day 103120 ± 41
PrimaryPK: AUC[0-∞] of LY3484356 (Cohort 4)

AUC\[0-∞\] of LY3484356

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 18: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
Reported as:
Geometric mean · ng*hr/mL
PK: AUC[0-∞] of LY3484356 (Cohort 4)
ng*hr/mLCohort 4: LY3484356 + Carbamazepine
Day 11950 ± 67
Day 181090 ± 32
PrimaryPK: Time of Maximum Observed Concentration (Tmax) of LY3484356 (Cohort 1)

PK: Tmax of LY3484356

Time frame:
Period 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 h postdose; Period 2: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 and 96 h postdose
Reported as:
Median · hours
PK: Time of Maximum Observed Concentration (Tmax) of LY3484356 (Cohort 1)
hoursCohort 1: 400 mg LY3484356 FastedCohort 1: 400 mg LY3484356 Fed
PK: Time of Maximum Observed Concentration (Tmax) of LY3484356 (Cohort 1)8.00 (3.00 to 35.80)3.02 (2.00 to 8.00)
PrimaryPK: Tmax of LY3484356 (Cohort 2)

PK: Tmax of LY3484356

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 9: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
Reported as:
Median · hours
PK: Tmax of LY3484356 (Cohort 2)
hoursCohort 2: LY3484356 + Omeprazole
Day 16.02 (1.00 to 10.00)
Day 96.00 (4.00 to 36.00)
PrimaryPK: Tmax of LY3484356 (Cohort 3)

PK: Tmax of LY3484356

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 10: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
Reported as:
Median · hours
PK: Tmax of LY3484356 (Cohort 3)
hoursCohort 3: LY3484356 + Itraconazole
Day 16.00 (2.00 to 36.00)
Day 106.00 (1.00 to 12.00)
PrimaryPK: Tmax of LY3484356 (Cohort 4)

Tmax of LY3484356

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 18: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
Reported as:
Median · hours
PK: Tmax of LY3484356 (Cohort 4)
hoursCohort 4: LY3484356 + Carbamazepine
Day 14.00 (2.00 to 36.00)
Day 183.87 (1.00 to 8.00)
PrimaryPK: Maximum Observed Concentration (Cmax) of LY3484356 (Cohort 1)

Cmax of LY3484356

Time frame:
Period 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 h postdose; Period 2: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 and 96 h postdose
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
PK: Maximum Observed Concentration (Cmax) of LY3484356 (Cohort 1)
nanogram per millilitre (ng/mL)Cohort 1: 400 mg LY3484356 FastedCohort 1: 400 mg LY3484356 Fed
PK: Maximum Observed Concentration (Cmax) of LY3484356 (Cohort 1)37.2 ± 51143 ± 28
PrimaryPK: Cmax of LY3484356 (Cohort 2)

Cmax of LY3484356

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 9: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of LY3484356 (Cohort 2)
ng/mLCohort 2: LY3484356 + Omeprazole
Day 149.1 ± 61
Day 939.6 ± 47
PrimaryPK: Cmax of LY3484356 (Cohort 3)

Cmax of LY3484356

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 10: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of LY3484356 (Cohort 3)
ng/mLCohort 3: LY3484356 + Itraconazole
Day 130.3 ± 57
Day 1056.7 ± 47
PrimaryPK: Cmax of LY3484356 (Cohort 4)

Cmax of LY3484356

Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose; Day 18: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 h postdose
Reported as:
Geometric mean · ng/mL
PK: Cmax of LY3484356 (Cohort 4)
ng/mLCohort 4: LY3484356 + Carbamazepine
Day 149.6 ± 76
Day 1833.3 ± 41

Adverse events

Collected over Cohort 1: up to 19 days, Cohort 2: up to 24 days, Cohort 3: up to 27 days, Cohort 4: up to 37 days, and Cohort 5: up to 25 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: 400 mg LY3484356 Fasted0/8 (0%)0/8 (0%)1/8 (12.5%)
Cohort 1: 400 mg LY3484356 Fed0/8 (0%)0/8 (0%)1/8 (12.5%)
Cohort 2: 400 mg LY3484356 (Day 1)0/10 (0%)0/10 (0%)2/10 (20%)
Cohort 2: 40 mg Omeprazole (Days 5 to 8)0/10 (0%)0/10 (0%)2/10 (20%)
Cohort 2: 400 mg LY3484356 + 40 mg Omeprazole (Day 9)0/9 (0%)0/9 (0%)1/9 (11.1%)
Cohort 3: 200 mg LY3484356 (Day 1)0/20 (0%)0/20 (0%)5/20 (25%)
Cohort 3: 200 mg Itraconazole (Days 5 to 9)0/20 (0%)0/20 (0%)8/20 (40%)
Cohort 3: 200 mg LY3484356 + 200 mg Itraconazole (Days 10 to 16)0/20 (0%)0/20 (0%)2/20 (10%)
Cohort 4: 400 mg LY3484356 (Day 1)0/29 (0%)0/29 (0%)2/29 (6.9%)
Cohort 4: 100 mg Carbamazepine (Days 6 to 8)0/28 (0%)0/28 (0%)1/28 (3.6%)
Cohort 4: 200 mg Carbamazepine (Days 9 to 11)0/28 (0%)0/28 (0%)6/28 (21.4%)
Cohort 4: 300 mg Carbamazepine + 400 mg LY3484356 (Days 12 to 22)0/28 (0%)1/28 (3.6%)16/28 (57.1%)
Cohort 4: 300 mg Carbamazepine (Day 23)0/20 (0%)0/20 (0%)3/20 (15%)
Cohort 5: 1.2 mg Midazolam (Day 1)0/15 (0%)0/15 (0%)0/15 (0%)
Cohort 5: 100 mg Carbamazepine (Days 2 to 4)0/15 (0%)0/15 (0%)1/15 (6.7%)
Cohort 5: 200 mg Carbamazepine (Days 5 to 7)0/15 (0%)0/15 (0%)0/15 (0%)
Cohort 5: 300 mg Carbamazepine (Days 8 to 10)0/15 (0%)0/15 (0%)2/15 (13.3%)
Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 11)0/15 (0%)0/15 (0%)1/15 (6.7%)
Cohort 5: 300 mg Carbamazepine (Days 12 to 13)0/15 (0%)0/15 (0%)2/15 (13.3%)
Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 14)0/14 (0%)0/14 (0%)0/14 (0%)
Most frequent serious events
Most frequent serious events
EventCohort 1: 400 mg LY3484356 FastedCohort 1: 400 mg LY3484356 FedCohort 2: 400 mg LY3484356 (Day 1)Cohort 2: 40 mg Omeprazole (Days 5 to 8)Cohort 2: 400 mg LY3484356 + 40 mg Omeprazole (Day 9)Cohort 3: 200 mg LY3484356 (Day 1)Cohort 3: 200 mg Itraconazole (Days 5 to 9)Cohort 3: 200 mg LY3484356 + 200 mg Itraconazole (Days 10 to 16)Cohort 4: 400 mg LY3484356 (Day 1)Cohort 4: 100 mg Carbamazepine (Days 6 to 8)Cohort 4: 200 mg Carbamazepine (Days 9 to 11)Cohort 4: 300 mg Carbamazepine + 400 mg LY3484356 (Days 12 to 22)Cohort 4: 300 mg Carbamazepine (Day 23)Cohort 5: 1.2 mg Midazolam (Day 1)Cohort 5: 100 mg Carbamazepine (Days 2 to 4)Cohort 5: 200 mg Carbamazepine (Days 5 to 7)Cohort 5: 300 mg Carbamazepine (Days 8 to 10)Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 11)Cohort 5: 300 mg Carbamazepine (Days 12 to 13)Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 14)
Hepatitis eInfections and infestations0/80/80/100/100/90/200/200/200/290/280/281/280/200/150/150/150/150/150/150/14
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCohort 1: 400 mg LY3484356 FastedCohort 1: 400 mg LY3484356 FedCohort 2: 400 mg LY3484356 (Day 1)Cohort 2: 40 mg Omeprazole (Days 5 to 8)Cohort 2: 400 mg LY3484356 + 40 mg Omeprazole (Day 9)Cohort 3: 200 mg LY3484356 (Day 1)Cohort 3: 200 mg Itraconazole (Days 5 to 9)Cohort 3: 200 mg LY3484356 + 200 mg Itraconazole (Days 10 to 16)Cohort 4: 400 mg LY3484356 (Day 1)Cohort 4: 100 mg Carbamazepine (Days 6 to 8)Cohort 4: 200 mg Carbamazepine (Days 9 to 11)Cohort 4: 300 mg Carbamazepine + 400 mg LY3484356 (Days 12 to 22)Cohort 4: 300 mg Carbamazepine (Day 23)Cohort 5: 1.2 mg Midazolam (Day 1)Cohort 5: 100 mg Carbamazepine (Days 2 to 4)Cohort 5: 200 mg Carbamazepine (Days 5 to 7)Cohort 5: 300 mg Carbamazepine (Days 8 to 10)Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 11)Cohort 5: 300 mg Carbamazepine (Days 12 to 13)Cohort 5: 300 mg Carbamazepine + 1.2 mg Midazolam (Day 14)
DizzinessNervous system disorders0/80/80/100/100/91/200/200/200/290/282/289/280/200/150/150/150/150/150/150/14
DiarrhoeaGastrointestinal disorders0/80/81/101/100/91/206/200/200/290/280/280/280/200/150/150/150/150/150/150/14
HeadacheNervous system disorders0/80/80/101/100/92/201/200/200/290/281/287/280/200/150/150/150/150/150/150/14
Covid-19Infections and infestations0/80/80/100/100/90/200/200/200/290/280/282/283/200/150/150/150/150/150/150/14
NauseaGastrointestinal disorders0/80/80/100/100/90/200/201/200/290/280/284/280/200/150/150/150/150/150/150/14
SomnolenceNervous system disorders0/80/80/100/100/90/200/200/200/290/282/280/280/200/150/150/152/150/150/150/14
Abdominal painGastrointestinal disorders1/80/80/101/100/90/201/200/201/290/280/280/280/200/150/150/150/150/150/150/14
ConstipationGastrointestinal disorders0/81/81/100/100/91/200/200/201/291/283/283/280/200/150/150/150/151/150/150/14
Nasal congestionRespiratory, thoracic and mediastinal disorders0/80/80/100/101/90/200/200/200/290/280/280/280/200/150/150/150/150/150/150/14
Amylase increasedInvestigations0/80/80/101/100/90/200/200/200/290/280/280/280/200/150/150/150/150/150/150/14

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Cohort 1: Sequence 1/Sequence 2Cohort 2: LY3484356 + OmeprazoleCohort 3: LY3484356 + ItraconazoleCohort 4: LY3484356 + CarbamazepineCohort 5: Carbamazepine + MidazolamTotal
Mean51.8 ± 6.958.6 ± 6.952.5 ± 9.249.8 ± 10.146.4 ± 10.451.1 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Sequence 1/Sequence 2Cohort 2: LY3484356 + OmeprazoleCohort 3: LY3484356 + ItraconazoleCohort 4: LY3484356 + CarbamazepineCohort 5: Carbamazepine + MidazolamTotal
Female8102029370
Male00001212
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Sequence 1/Sequence 2Cohort 2: LY3484356 + OmeprazoleCohort 3: LY3484356 + ItraconazoleCohort 4: LY3484356 + CarbamazepineCohort 5: Carbamazepine + MidazolamTotal
Hispanic or Latino351118845
Not Hispanic or Latino55911737
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Sequence 1/Sequence 2Cohort 2: LY3484356 + OmeprazoleCohort 3: LY3484356 + ItraconazoleCohort 4: LY3484356 + CarbamazepineCohort 5: Carbamazepine + MidazolamTotal
American Indian or Alaska Native100001
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American3328218
White4718211363
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Sequence 1/Sequence 2Cohort 2: LY3484356 + OmeprazoleCohort 3: LY3484356 + ItraconazoleCohort 4: LY3484356 + CarbamazepineCohort 5: Carbamazepine + MidazolamTotal
United States81020291582
08

Study locations

2 sites
  • LabCorp CRU, Inc.
    Daytona Beach, Florida 32117, United States
  • Covance Dallas
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Apr 2022, 11 months.

Results were first posted in Dec 2025, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2021
First posted
Apr 12, 2021
StartActual
Apr 26, 2021
Primary completionActual
Apr 12, 2022
CompletionActual
Apr 12, 2022
Results first posted
Dec 11, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04840888
Responsible party
Sponsor
First posted
Apr 12, 2021
Start date
Apr 26, 2021
Primary completion
Apr 12, 2022
Completion
Apr 12, 2022
Results posted
Dec 11, 2025
Last update
Dec 11, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Imlunestrant · Carbamazepine

Start the discussion